News Article
EQT acquires molecular diagnostics specialist in €10.80bn takeover
Swedish private equity group EQT is acquiring listed German-Dutch diagnostics specialist Qiagen in a transaction that values the target at an enterprise value of approximately €10.80bn.
The transaction represents a major consolidation in the European life sciences and molecular diagnostics landscape. Qiagen operates extensively across sample preparation, molecular diagnostics, and life sciences research fields, with its technologies widely deployed in clinical laboratories and pharmaceutical research facilities worldwide.
The board of Qiagen has unanimously endorsed the agreement with EQT after exploring a range of strategic alternatives and evaluating potential bids from other interested parties.
The transaction remains subject to several closing conditions and is currently projected to close in mid-2027.
